A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Ilodecakin (Primary) ; Capecitabine; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Nivolumab; Oxaliplatin; Paclitaxel; Pazopanib; Pembrolizumab
  • Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors ARMO Biosciences
  • Most Recent Events

    • 05 Jun 2018 Results of cohort of patients with non-small cell lung cancer (n=34) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results reporting the safety, efficacy and overall survival of AM0010 + FOLFOX as 2nd and later line treatment in pancreatic adenocarcinoma patients presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results assessing the safety of Pegilodecakin with nivolumab or pembrolizumab in patients with mCRC (n=38) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top